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Abstract
Introduction Female germline BRCA gene mutation carriers are
at increased risk for developing breast cancer. The purpose of
our study was to establish whether healthy BRCA mutation
carriers demonstrate an increased frequency of aberrant gene
promoter hypermethylation in ductal lavage (DL) fluid, compared
with predictive genetic test negative controls, that might serve
as a surrogate marker of BRCA1/2 mutation status and/or
breast cancer risk.
Methods The pattern of CpG island hypermethylation within the
promoter region of a panel of four genes (RAR-β, HIN-1, Twist
and Cyclin D2) was assessed by methylation-specific
polymerase chain reaction using free DNA extracted from DL
fluid.
Results Fifty-one DL samples from 24 healthy women of known
BRCA mutation status (7 BRCA1 mutation carriers, 12 BRCA2
mutation carriers and 5 controls) were available for methylation
analysis. Eight of 19 (42.1%) BRCA mutation carriers were
found to have at least one hypermethylated gene in the four-
gene panel. Two BRCA mutation carriers, in whom aberrant
methylation was found, also had duct epithelial cell atypia
identified. No hypermethylation was found in DL samples from 5
negative controls(p = 0.13).
Conclusion We found substantial levels of aberrant
methylation, with the use of a four-gene panel, in the fluid from
the breasts of healthy BRCA mutation carriers compared with
controls. Methylation analysis of free DNA in DL fluid may offer
a useful surrogate marker for BRCA1/2 mutation status and/or
breast cancer risk. Further studies are required for the evaluation
of the specificity and predictive value of aberrant methylation in
DL fluid for future breast cancer development in BRCA1/2
mutation carriers.
Introduction
Women carrying pathogenic gene mutations in either BRCA1
or BRCA2 are at significantly increased lifetime risk of up to
80% for developing breast cancer [1]. A significant proportion
of this risk occurs in women under the age of 50 years. Current
surveillance recommendations include mammographic
screening and clinical breast examination [2]. It is well recog-
nised that mammograms are less sensitive in younger women,
who have more radiodense breast tissue, and although alter-
native imaging modalities such as magnetic resonance imag-
ing have shown promise there is still a clear need for better risk
assessment and earlier breast cancer detection in this high-
risk group [3,4]. Ductal lavage (DL) is a novel method for
repeated minimally invasive sampling of breast ductal fluid,
allowing the safe collection of cells sufficient for cytological
diagnosis and providing a source of cellular and free DNA forPage 1 of 9
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cell atypia, identified by DL, for breast cancer development is
currently being assessed in the ongoing multicentre SEDE
(Serial Evaluation of Ductal Epithelium) trial in women with
moderate and high risk for breast cancer on the basis of family
history criteria.
Over 60 women from known BRCA gene mutation carrying
families are taking part in the ductal research programme at
the Royal Marsden NHS Foundation Trust, which is evaluating
the usefulness of nipple aspiration (NA) and DL as risk assess-
ment tools in this group. We are using DL to investigate epi-
thelial cell atypia rates among BRCA mutation carriers and are
performing a variety of molecular and proteomic analyses on
the ductal fluid collected in the search for surrogate biomark-
ers of breast cancer risk.
CpG islands are short regions of DNA containing clusters of
CpG dinucleotides that are generally unmethylated in normal
somatic cells. Hypermethylation of cytosine residues in CpG
islands within the gene promoter is recognised as an impor-
tant epigenetic mechanism of transcriptional silencing during
early cancer development [6]. Key targets of aberrant pro-
moter hypermethylation in breast cancer development include
genes involved in all stages of tumorigenesis such as DNA
repair (BRCA1), receptors (ER, RAR-β), intracellular signalling
pathways, cell cycle regulation (Cyclin D2, p16INK4A), tran-
scription factors (Twist), adhesion molecules (E-cadherin) and
apoptosis (HOXA5) [7-14]. Gene promoter hypermethylation
of RAR-β, HIN-1, Cyclin D2 and Twist has been reported to
be a frequent and tumour specific event in in situ and invasive
breast cancer of both ductal and lobular types [10]. In this
study we sought to determine whether there was an associa-
tion between hypermethylation of four candidate tumour sup-
pressor genes, implicated in breast carcinogenesis, and
underlying BRCA gene mutation status.
The observation that levels of cell-free DNA are higher in the
body fluids of cancer patients than in healthy controls has led
to interest in its use in the screening and early diagnosis of
cancer [15]. Cancer-specific DNA methylation patterns have
been found in exfoliated luminal tumour cells and free tumour
DNA from a variety of body fluids including urinary sediment,
saliva, sputum, bronchial washings and ejaculate [16-21]. Pre-
vious studies have reported the methylation patterns of cellular
DNA from nipple aspirates and DL fluid obtained from women
with breast cancer compared with those with benign breast
disease and healthy controls. The use of free DNA from DL
fluid for methylation profiling is novel [22,23].
Methylation-specific PCR (MSP) requires only small quantities
of DNA, has high specificity and is sensitive enough to identify
one methylated allele among 1,000 unmethylated alleles [24].
Aberrant hypermethylation of CpG islands, being uncommon
in normal cells and an early event in cancer development, is a
good candidate for a biomarker of breast cancer risk. Breast
ductal fluid can be repeatedly sampled in a minimally invasive
way, and methylation analysis, in conjunction with cytological
diagnosis, potentially offers a further tool for assessing individ-
ual risk for developing breast cancer.
Materials and methods
Subjects
Prospective locoregional ethics committee approval was
gained for a study evaluating the usefulness of DL as a breast
cancer risk assessment tool in women from families carrying
the BRCA1/2 gene mutation who attended the Cancer
Genetics Carrier Clinic at the Royal Marsden Foundation NHS
Trust. This ongoing study is comparing breast ductal epithelial
cell atypia rates in the lavage fluid of BRCA gene mutation car-
riers with true negative controls (women who have had a neg-
ative predictive genetic test for a known BRCA1 or BRCA2
mutation present in the family). All women had had a normal
clinical breast examination and mammogram within 12 months
of the sample collection and gave informed consent before
entry to the study. DL was attempted on all healthy breasts
unaffected by previous cancer; where possible, multiple ducts
in the same breast were cannulated. Fifty-one DL specimens
were available for methylation pattern analysis from 24 women,
of whom 19 were BRCA mutation carriers (7 BRCA1 and 12
BRCA2) and 5 were negative controls on the basis of the pre-
dictive genetic test. Eight of the 51 DL samples were repeat
samples from individual ducts, identified by marking the duct
position on a grid, from 6 BRCA mutation carriers collected 1
year apart. Five of the BRCA2 mutation carriers had previously
been affected by unilateral breast cancer (three with invasive
ductal carcinoma, two with invasive lobular cancer) but were
currently disease free.
Specimen collection and processing
Topical anaesthetic cream was applied to the nipple and are-
ola 1 hour before DL was performed, and 0.5 to 1.0 ml of 1%
lignocaine was injected subcutaneously at the base of the nip-
ple as this was found to improve tolerability. DL was otherwise
performed as described by Dooley and colleagues with the
modification that lavage was attempted of both nipple aspirate
fluid-yielding and non fluid-yielding ducts [5]. The DL fluid was
collected into 15 ml Falcon tubes and then centrifuged at
1,500 r.p.m. for 10 minutes at 4°C. Two slides, produced
using the Shandon cytospin technique from the cellular frac-
tion of the DL sample, were Giemsa-stained for cytological
assessment. Slides were deemed adequate for cytological
diagnosis if more than 10 epithelial cells were present. Slides
with fewer than 10 epithelial cells were considered to contain
inadequate cellular material for diagnosis (ICMD). Slides with
sufficient epithelial cells for diagnosis were further categorised
as benign ductal epithelial cells, mildly atypical epithelial cells,
markedly atypical cells or malignant epithelial cells. Cytological
assessment was performed by breast cytopathologists (PO
and AN) blinded to the genetic status of the subject. The DLPage 2 of 9
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at -80°C for later DNA extraction. Free DNA was extracted
from 200 μl of DL supernatant, using the DNeasy Tissue Kit
(Qiagen, Hilden, Germany) in accordance with the manufac-
turer's instructions, and eluted in 50 μl of the AE buffer pro-
vided in the kit. Unmethylated control samples consisted of 1
mg/ml solutions of human sperm DNA (HSD), and methylated
controls were 1 mg/ml solutions of DNA extracted from the
MDA-MB-231 breast cancer cell line (231), both provided
courtesy of Mary Jo Fackler (Johns Hopkins University School
of Medicine, Baltimore, MD, USA).
Sodium bisulphite conversion
Sodium bisulphite and alkaline treatment of genomic DNA
converts unmethylated cytosine residues to uracil, leaving
methylated cytosine residues unchanged. These methylation-
dependent sequence variants at a specific locus can subse-
quently be analysed by PCR amplification by using primers
specific for the unmethylated or methylated sequence. A mod-
ification of the method described by Herman and colleagues
was used for the sodium bisulphite conversion of both DL
supernatant DNA samples and the unmethylated/methylated
control samples [24]. In brief, either 13.5 μl of the DL super-
natant DNA solution containing 600 μg of salmon sperm DNA
carrier or 1 μl control DNA with 12.5 μl TNES (10 mM Tris-HCl
pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.5% SDS) containing
830 ng of salmon sperm DNA was heated to 99°C for 10 min-
utes. After the addition of 1.5 μl of 2 M NaOH, the sample was
incubated at 42°C for 30 minutes. Sodium bisulphite (3.6 M,
95 μl) containing 1 mM hydroquinone was added to each sam-
ple, which was then overlaid with three drops of mineral oil and
incubated for 5 hours at 55°C in the dark. Two 50 μl aliquots
taken from each of the sodium bisulphite modified DNA sam-
ples were applied separately to two S-200 Microspin columns
(Amersham, Needham, MA, USA) and purified in accordance
with the manufacturer's instructions. The DNA eluted from
both columns was pooled in a 1.5 ml microtube with 10 μl of
3 M NaOH and chilled on ice for 5 minutes. Subsequently 275
μl of sterile water, 125 μl of 7.5 M ammonium acetate and 3 μl
of glycogen were added to each sample and the mixture
chilled for a further 5 minutes on ice. DNA was precipitated
using 1 ml of absolute ethanol, washed in 1 ml of 75% ethanol
and redissolved in 10 μl of water. The sample was stored at -
80°C until use.
Methylation analysis
Methylation analysis was performed with a two-stage PCR
technique. An initial multiplex PCR reaction was performed to
co-amplify template DNA in the promoter region of four genes
(RAR-β, HIN-1, TWIST and Cyclin D2). Either 4 μl (DL sam-
ples) or 1 μl (HSD/231 controls) of the purified sodium bisul-
phite converted DNA solution were included in a 25 μl PCR
reaction buffer (16.6 mM (NH4)2SO4, 67 mM Tris-HCl pH 8.8,
6.7 mM MgCl2, 10 mM 2-mercaptoethanol, 0.1% dimethylsul-
phoxide, 1.25 mM dNTP mixture) also containing 5 units of
Platinum Taq (Invitrogen, Carlsbad, CA, USA) and 100 ng
each of the forward and reverse primers specific for the four-
gene panel of interest. Primer sequences and PCR conditions
for the multiplex step were as described by Fackler and col-
leagues [25]. The PCR products were diluted to a total volume
of 125 μl with water and stored at -20°C. The HSD and 231
controls were further diluted 1:1,000 with water.
The second stage was a methylation-specific PCR reaction.
Diluted DNA (1 μl) from the multiplex PCR reaction was added
to a 24 μl PCR reaction buffer described above containing 2.5
units of RedTaq (Sigma, St Louis, MO, USA) and 100 ng each
of the forward and reverse primers specific for either the
unmethylated or methylated variants of the gene of interest
after sodium bisulphite conversion. All primer sets were
obtained from Invitrogen, and the sequences have been
reported previously [10]. PCR products were separated on a
2% agarose electrophoresis gel. Replicate MSP reactions
were performed at least twice to ensure reproducibility of
results.
Statistical analysis
Fisher's exact test (two-sided) was used to compare the pro-
portion of BRCA mutation carriers and controls with hyper-
methylation in their DL samples.
Results
Fifty-one DL samples from 24 healthy women of known BRCA
status (7 BRCA1 carriers, 12 BRCA2 carriers and 5 controls)
were available for methylation analysis. A mean of 1.2 ducts
were successfully cannulated per breast on each visit. The
mean ages of BRCA mutation carriers and controls at their
first DL sample collection were 44.9 years (range 34.3 to 62.8
years) and 50.4 years (range 41.4 to 55.4 years), respectively.
Thirty-eight of the 51 DL samples contained adequate cells for
cytological diagnosis (74.5%). Thirty-six of the 51 DL samples
demonstrated benign cytology (70.6%) and two samples from
BRCA mutation carriers demonstrated mild atypia (3.9%). A
further 13 of the 51 samples were classified as ICMD. No aty-
pia was identified in the DL samples from predictive genetic
test negative controls.
Free DNA sufficient for PCR amplification was obtained from
the supernatant of 49 of 51 DL samples. Eight of 19 (42.1%)
mutation carriers were found to have at least one hypermeth-
ylated gene in the four-gene panel, in comparison with none of
the 7 DL samples obtained from 5 negative controls (p =
0.13). We found HIN-1 to be the most frequently methylated
gene and CyclinD2 the least frequently methylated gene in the
panel (Table 1). Representative examples of methylated DL
samples are shown in Figure 1. Four of the eight BRCA muta-
tion carriers, in whom aberrant methylation was found, demon-
strated simultaneous methylation of two different genes in the
four-gene panel – two BRCA mutation carriers in the same DL
sample (subjects 1 and 13) and two BRCA mutation carriersPage 3 of 9
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tion carrier (subject 6) was found to have hypermethylation of
RAR-β in a DL sample from the left breast at her first visit and
hypermethylation of HIN-1 in a repeat sample taken from the
same duct 1 year later (Figure 2).
Two BRCA mutation carriers, in whom aberrant methylation
was demonstrated, also had asymptomatic duct epithelial cell
atypia. The first, a BRCA1 mutation carrier (subject 3), had
mild atypia identified in a DL sample taken from the right breast
at her initial DL visit. Although aberrant methylation was not
identified in the DL samples taken at this time, hypermethyla-
tion of RAR-β and Twist was subsequently found in DL sam-
ples taken from the same breast 1 year later. The second, a
BRCA2 mutation carrier (subject 11), was known to have per-
sistent mild atypia in both breasts on repeat nipple aspirate
cytology in a previous study. Mild atypia was identified in a DL
sample taken from the right breast, and MSP analysis of DNA
extracted from the same duct revealed hypermethylation of
HIN-1. At the same visit hypermethylation of RAR-β was found
in a DL sample taken from the left breast although on this
occasion DL cytology was benign.
Clearly, reproducibility is an important issue if hypermethyla-
tion is to be a useful biomarker of breast cancer risk, and rep-
licate PCR experiments showed our assay to be robust. We
examined reproducibility of the methylation analysis over time,
in a subgroup of women, by repeat sampling of DL fluid from
individual marked ducts 1 year apart. We found that the pres-
ence of methylation was not always consistent but that in most
ducts the change in methylation status was from unmethylated
to methylated, which could represent an alteration in risk over
time. There was no statistically significant association
between age and the presence of hypermethylation in BRCA
mutation carriers. Hypermethylation was more commonly
found in premenopausal (6 of 12 women) than
postmenopausal (2 of 7 women) BRCA mutation carriers, but
this did not reach statistical significance.
Three of the five BRCA2 mutation carriers previously affected
by contralateral breast cancer were found to have aberrant
methylation in DL samples from their healthy breasts. Of those
previously affected by contralateral invasive ductal carcinoma,
two were found have hypermethylation of HIN-1 and one also
had hypermethylation of Cyclin D2. One of the two DL sam-
Table 1
Frequency of hypermethylated genes in BRCA gene mutation carriers and controls
Group n Frequency of hypermethylated genes (percentage)
HIN-1 RAR-β Twist Cyclin D2
BRCA carriers 19 5 (26) 4 (21) 3 (16) 1 (5)
Controls 5 0 (0) 0 (0) 0 (0) 0 (0)
Figure 1
Representative methylation analysis of DL samples from BRCA carriers in whom aberrant methylation was found. (a) Hypermethylation of RAR-β 
found in ductal lavage (DL) samples from subjects 17, 11, 3 and 6. Replicate PCR experiments for subject 11, using DNA from the same duct, are 
shown to illustrate reproducibility. (b) Methylation analysis of HIN-1. Two different ducts for subject 1 are shown: the first is unmethylated (duct right 
2a; see Figure 2) and the second shows hypermethylation of HIN-1 (duct right 1a). Subjects 11, 13 and 8 show aberrant methylation of HIN-1. In 
both panels, unmethylated control samples consisted of 1 mg/ml solutions of human sperm DNA (HSD), and methylated controls were 1 mg/ml 
solutions of DNA extracted from the MDA-MB-231 breast cancer cell line (231). Marker used is a 123bp DNA ladder - rungs represent 123bp, 
246bp and 369bp. M, methylated; U, unmethylated.Page 4 of 9
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demonstrated aberrant methylation of Twist. None of the
women taking part in this study have been diagnosed with a
new primary breast cancer during a median length of follow-up
of 32 months (range 17 to 38 months).
Figure 2
Methylation analysis of four-gene panel in DL fluid from BRCA1 and BRCA2 carriers and controlsf  l i  L fluid from BRCA1 and BRCA2 carriers and controls. The genes in the panel were HIN-1, RAR-β, Twist 
and Cyclin D2. Ducts are identified as being from the left or right breast. Individual ducts are identified sequentially as a, b or c. The suffix 1 or 2 indi-
cates the first or second lavage visit, respectively, for ducts from which repeat samples were taken 1 year apart. For example, left a2 indicates that a 
sample was taken from the left breast, duct a at the second ductal lavage (DL) visit. Black boxes indicate methylated genes, white boxes indicate 
unmethylated genes, and grey boxes indicate repeated failure of PCR reaction or inconclusive result. *Subject 11 had long-standing atypia identified 
in both breasts on nipple aspirate fluid cytology. **BRCA2 carriers affected by contralateral breast cancer. DL samples were collected from only 
their healthy unaffected breasts. ICMD, insufficient cellular material for diagnosis.Page 5 of 9
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with the fluid-yielding status of the duct or DL sample cellular-
ity. Large population-based studies of nipple aspirate cytology
have shown that women who do not yield NA fluid have the
lowest risk for developing breast cancer and that women pro-
ducing NA fluid with benign cytology have a relative risk for
developing breast cancer of 1.2 to 1.6 compared with those
who do not yield NA fluid [26]. Recent studies of DL in
BRCA1/2 mutation carriers have examined the influence of
various hormonal factors on fluid-yielding status and DL sam-
ple cellularity. Younger age and premenopausal status are pre-
dictive of higher DL fluid yields and increased sample
cellularity [27,28]. Furthermore, an inverse correlation exists
between fluid-yielding status and previous treatment for breast
or ovarian cancer with therapies likely to impair ovarian func-
tion, suggesting the importance of oestrogen in maintaining
the proliferative status of the breast ductal epithelium [27].
In our study, of the 44 DL samples from BRCA mutation carri-
ers, 34 samples were from fluid-yielding ducts and 10 from
ducts not yielding fluid. Interestingly, all 11 DL samples dem-
onstrating aberrant methylation were from ducts that yielded
fluid with nipple suction aspiration. Methylation was also found
more commonly in cellular DL samples than in samples that
were ICMD. However, the predictive value of fluid-yielding sta-
tus and cellular atypia in DL fluid for breast cancer develop-
ment remains unproven in prospective trials. Indeed, some
studies have reported similar rates of DL atypia for both fluid-
yielding ducts and those not yielding fluid, suggesting that dry
ducts may carry a higher risk of breast cancer than previously
thought [27,29].
Discussion
Women carrying a germline heterozygous mutation in either
BRCA1 or BRCA2 are predisposed to breast and ovarian
cancer. DL has been shown to be a safe and feasible method
for retrieving breast ductal epithelial cells and sampling their
surrounding ductal microenvironment in a minimally invasive
way [5]. Studies have shown early promise in identifying
potential markers of breast cancer risk in ductal fluid, but vali-
dation of these potential molecular markers and further evalu-
ation of the ductal approach to establish the sensitivity and
specificity for early breast cancer detection is required
[22,30,31]. DL cytology alone has been found to have a low
sensitivity for the detection of established breast cancer, but
this may be improved by markers such as gene promoter
hypermethylation [32,33].
Hypermethylation of gene promoter regions is an early event in
breast carcinogenesis; cancer-specific DNA methylation pro-
files of free tumour DNA in blood and other body fluids have
been reported, but the diagnostic potential of DNA methyla-
tion profiling remains largely unexplored [28]. NA and DL offer
the potential for repeatedly collecting breast epithelial cells
and ductal fluid, providing a source of both cellular and free
DNA for methylation studies. Krassenstein and colleagues
studied the methylation patterns of a six-gene panel (GSTP1,
RAR-β, RASSF1A, DAP-kinase, p16INK4a and p14ARF) in 22
paired breast tumour and nipple aspirate fluid (NAF) DNA
samples [23]. Hypermethylation of at least one gene was
present in all 22 of the tumour samples, and in 18 (82%) of the
matched nipple aspirate specimens the same genes were
methylated. However, not all women produce NAF and in our
experience only about 40% of BRCA mutation carriers are
fluid yielders (Locke I, unpublished data). This figure is similar
to that reported in a previous study of NA and DL in BRCA
mutation carriers and may reflect the increasing use of risk
reduction strategies, such as bilateral prophylactic oophorec-
tomy and chemopreventative agents, which are associated
with a reduced rate of NAF production and consequently limit
the utility of methylation profiling of NAF in this group as a risk
assessment tool [27,34].
DL has the advantage of providing a more cellular yield than
NAF; furthermore DL is often possible in non-NAF producers,
potentially making it a more clinically useful source of DNA for
methylation studies. Evron and colleagues [22] reported that
methylation analysis, with a three-gene marker panel (Cyclin
D2, RAR-β and Twist), of DNA from the exfoliated cells in 56
DL samples from asymptomatic women at increased risk for
developing breast cancer (Gail risk at least 1.7-fold) had a
sensitivity of 67% and a specificity of 89% for the detection of
severely atypical or malignant epithelial cells. In our study we
used free DNA extracted from the DL supernatant to allow the
relatively limited cellular component of the DL sample to be
conserved for cytological assessment and other molecular
studies.
Free DNA from DL supernatant has previously been used to
perform loss-of-heterozygosity analyses at the BRCA1 and
FHIT loci and for the detection of mitochondrial DNA muta-
tions in BRCA1 mutation carriers and controls, although ques-
tions have been raised about the robustness of these analyses
[30,35,36]. The use of free DNA in DL fluid for methylation
profiling has not previously been reported.
In our study, we assessed the methylation pattern of free DNA
from DL fluid by using a small panel of genes implicated in
early breast carcinogenesis. Retinoids are derivatives of vita-
min A that bind to the RAR receptor and have chemopreventa-
tive potential mediated through their function in regulating
cellular growth and differentiation. Retinoids have been found
to inhibit the growth of breast cancer cells in culture and
breast tumours in animal models [37]. Methylation of the RAR-
β promoter region in breast cancer tumours and cell lines
shows an inverse correlation with the degree of RAR-β gene
expression; the gene is expressed and unmethylated in normal
breast tissue and in human mammary epithelial cells [9,38].
Hypermethylation of the RAR-β promoter is a frequent event in
both ductal and lobular breast cancer and has also been foundPage 6 of 9
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lymph node metastases, an important adverse prognostic fac-
tor [10,37].
HIN-1 is a putative cytokine, and promoter hypermethylation is
thought to confer insensitivity to antigrowth signals. HIN-1
expression is downregulated in most breast cancers; reintro-
duction of HIN-1 into breast cancer cell lines inhibits cell
growth, providing supporting evidence for its role as a candi-
date tumour suppressor gene [39]. Promoter hypermethyla-
tion of Cyclin D2, an important cell-cycle-regulatory gene that
controls the transition from G1 to S phase, has been
described in breast cancer. and its presence in ductal carci-
noma in situ suggests that transcriptional silencing of Cyclin
D2 by hypermethylation is an early event in breast tumorigen-
esis [11]. Twist, a basic helix – loop – helix transcription factor,
has been implicated in cell lineage differentiation and the inhi-
bition of oncogene-dependentand p53-dependent cell death.
Promoter hypermethylation of Twist may permit cells to evade
apoptosis and has been found to be a feature of both in situ
and invasive breast cancer, particularly of the ductal rather
than the lobular subtype [10,22].
We found HIN-1 and RAR-β to be more commonly hyper-
methylated than CyclinD2 or Twist in DNA from the DL fluid of
BRCA mutation carriers. Interestingly, this finding is similar to
that reported by previous authors for ductal carcinoma in situ
and lobular carcinoma in situ, suggesting that hypermethyla-
tion of HIN-1 and RAR-β genes is a frequent and early event
in breast carcinogenesis [10]. The four genes in the panel
used in this study have pivotal roles in cell cycle regulation, the
control of cell growth and p53-dependent apoptosis. Pro-
moter hypermethylation and consequent transcriptional silenc-
ing of HIN-1, RAR-β, Cyclin D2 and Twist may remove the
negative regulation of cell proliferation and apoptosis, allowing
uncontrolled cell growth and evasion of cell death.
We have demonstrated that it is feasible to perform an MSP
analysis for a panel of four genes with free DNA extracted from
the DL supernatant of both BRCA germline mutation carriers
and negative controls. Furthermore, it was possible to perform
these analyses on acellular samples in which a cytological
diagnosis is not possible, thus enhancing the potential diag-
nostic utility of the samples. We found evidence that methyla-
tion is a frequent event in the breasts of apparently healthy
BRCA mutation carriers who are at high risk for developing
breast cancer. Indeed, aberrant methylation was found in
42.1% of the BRCA mutation carriers but in none of five neg-
ative controls. Half of the BRCA mutation carriers in whom
hypermethylation was found demonstrated the simultaneous
methylation of two genes of the methylation panel. Although
the small number of controls limited the ability of our study to
reach statistical significance, the levels of methylation found
among BRCA mutation carriers were higher than would be
expected, because these genes are not commonly methylated
in normal breast tissue [40]. A larger study is under way to val-
idate the findings of this preliminary study.
DL is a technique that is prone to cell sampling variation, par-
ticularly when a relatively small atypical or malignant tumour
cell population exists within an abundant mixed normal cell
population. Similarly, the methylation pattern obtained from a
single DL sample reflects the heterogeneity of DNA molecules
sampled. Furthermore, the degree of CpG island methylation
is not likely to be uniform: it varies between different cells and
indeed between copies of the gene within the same cell.
These factors may contribute to the variation in the methylation
pattern of DL fluid between individual ducts and between sam-
ples taken from the same duct at different time points that we
found in this study. Atypia and aberrant methylation may both
reflect breast cancer risk status independently, and a com-
bined approach using cytological diagnosis and the evaluation
of DL methylation patterns offers the (as yet unproven) poten-
tial for refining the assessment of familial breast cancer risk.
High-throughput and more sensitive quantitative methodolo-
gies for methylation profiling have been reported with the abil-
ity to detect a single methylated allele among 105
unmethylated copies [25]. These techniques would have par-
ticular application to the methylation analysis of free DNA in DL
fluid, in which the DNA concentration is low. We plan to inves-
tigate hypermethylation in a larger DL sample set with a
broader panel of genes.
Conclusion
We conclude that performing methylation analyses of free
DNA from DL supernatant is feasible, and in our study we
found substantial levels of aberrant methylation in DL fluid from
healthy BRCA gene mutation carriers in comparison with con-
trols. Such epigenetic events may represent an early event in
breast tumorigenesis, with methylation analysis of free DNA
from DL fluid offering a useful alternative surrogate marker of
breast cancer risk, particularly when samples are insufficient
for cytological diagnosis, and/or they may be a marker of
BRCA1/2 mutation status. Further larger studies with long-
term follow-up are required for evaluating the specificity and
predictive value of these methylated markers in DL fluid for the
subsequent development of breast cancer.
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